Science Reveals Key Driver of Alzheimer’s, and How Newly Approved Drug May Fight It
WEDNESDAY, May 10, 2023 (HealthDay News) — Researchers have isolated for the first time a free-floating form of amyloid beta that appears to be a key driver of Alzheimer’s disease. Further, they argue that a newly approved Alzheimer’s drug — lecanemab (Leqembi) — directly targets these small, complex chains ofContinue Reading